Patent & IP news for July 12, 2016

High Court summarily dismisses Seretide combination color mark from ipkitten.blogspot.com

Face planting - the AmeriKat's new pastime after a summer
of political mayhemFor those readers who fancy a change from Brexit and UPC-fate related news, preferring instead a reminder of good, old fashioned IP ...

Share via E–mail | Twitter | Facebook

Amgen Inc. v. Apotex Inc. (Fed. Cir. 2016) from www.patentdocs.org

By Andrew Williams -- Last year, the Federal Circuit described the Biologics Price Competition and Innovation Act ("BPCIA") as "a riddle wrapped in a mystery inside of an enigma" in the Amgen v. Sandoz case. Nevertheless ...

Share via E–mail | Twitter | Facebook

Focus On Medicines Patents & Prices Alone May Do More Harm Than Good from www.ip-watch.org

Populism is in vogue these days and critics of pharmaceutical patents are trying to ride the wave, claiming that undermining patents will dramatically decrease prices but not reduce innovation. Both sides of that claim are ...

Share via E–mail | Twitter | Facebook

After Halo, Jury Finding Alone Sufficient to Support Judgment of Willfulness from docketreport.blogspot.com

The court granted plaintiff's motion for judgment as a matter of law that defendants willfully infringed its transformer patent based on the jury's finding of willful infringement. "[T]he jury returned a verdict ...

Share via E–mail | Twitter | Facebook

What impact should the UCC as authority have on patent eligible subject matter? from www.717madisonplace.com

In yesterday’s opinion in Medicines Co. v. Hospira, Inc., __ F.3d __ (Fed. Cir. 2016) (en banc), the Federal Circuit relied upon the Uniform Commercial Code in establishing a test for when an ...

Share via E–mail | Twitter | Facebook

How Are Licensors And Licensees Adapting To New Scenarios? from www.ip-watch.org

BARCELONA, Spain -- A recent industry conference panel here covered topics of changing intellectual property scenarios perceived from different angles, in particular from operating companies which manufacture products or services and patent assertion entities (PAEs).

Share via E–mail | Twitter | Facebook